InterMune (nasdaq)ITMN | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
InterMune (nasdaq)ITMN

An SI Board Since March 2000

Posts	SubjectMarks	Bans	Symbol
508	36	0	ITMN

Emcee: Secret_Agent_Man	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
458	Randomization was 2:2:1 (H:P:L). L weren't (by design) included in any seco	ghmm	-	2/3/2009
457	But there would have been half as many placebo patients in the 2nd trial. I th	rkrw	-	2/3/2009
456	I didn't quite catch it but there were big difference in non US vs US sites	ghmm	-	2/3/2009
455	They really ought to be required to repeat capacity 1. 95% powered study showed	rkrw	-	2/3/2009
454	<reply> The p value was excellent for Capacity 2. If I had IPF, I would	kenhott	-	2/3/2009
453	InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF	kenhott	-	2/3/2009
452	Would have rather seen CAPACITY 1 hit as that is the bigger trial (high dose).	ghmm	-	2/3/2009
451	0.501 p-value for Capacity 1 and .001 for the high dose Capacity 2. Strange. The	rkrw	-	2/3/2009
450	IF the TARP thing doesn't work out maybe we can start a shuttle service to J	ghmm	-	2/2/2009
449	What was your guess? <<I will be ready for TARP if I am wrong. I guess t	rkrw	-	2/2/2009
448	InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF	kenhott	1	2/2/2009
447	Surprising to see some strength. I've held for several years now. Not a hu	ghmm	-	1/16/2009
446	Nice period of strength, hope it works for you. I rode for a bit and enjoyed.	scaram(o)uche	-	1/16/2009
445	InterMune Reports Results from Triple Combination Study of ITMN-191 Click here	tnsaf	-	1/12/2009
444	IMO Feuerstein is more then a little biased. Its been pretty obvious he has bee	ghmm	-	1/12/2009
443	>> Pretty much look for it to be sold/shorted << I see what you mea	scaram(o)uche	-	1/12/2009
442	I think a lot of huff-n-puffers (as elsewhere) didn't meet the entry criteri	ghmm	-	1/10/2009
441	I don't think too much is read into what companies do. I'm not saying th	rkrw	-	1/9/2009
440	They CC stopping the actimmune IPF trial but that was Phase 3. Don't recall	ghmm	-	1/9/2009
439	I thought (worried) that too. In general too much is read into what companies d	ghmm	-	1/9/2009
438	Pretty much look for it to be sold/shorted. The data would have to be spectacula	rkrw	-	1/9/2009
437	So you're saying that holders should sell on any really good news, huh? OK.	scaram(o)uche	-	1/9/2009
436	sure!	scaram(o)uche	-	1/9/2009
435	On the other hand they have pivotal data for pirfenidone due any day, could they	rkrw	-	1/9/2009
434	ya don't usually conference call/webcast to talk about a failed 1b trial? W	scaram(o)uche	-	1/9/2009

Go to reply# or date (mm/dd/yy):